CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 101 enrolled
Drug / intervention
Carfilzomibdrug
Likely dose
Carfilzomib 27 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00884312
NCT00884312Phase 2Completed
CompareCT.gov

An Open-Label, Single-Arm, Phase 2 Study of Extended Carfilzomib Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols

Amgen·interventional·Posted Apr 20, 2009·Updated May 14, 2018

In Brief

A Phase 2 clinical trial evaluating Carfilzomib for Multiple Myeloma and Solid Tumors. Completed, enrolled 101 participants across 23 sites in 2 countries.

Detailed Summary

This is a multi-center, open-label, Phase 2 study of carfilzomib to monitor the safety and efficacy of long-term or continuing carfilzomib therapy for patients who previously completed a primary carfilzomib treatment study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Solid Tumors
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 20, 2009
Enrollment StartApr 9, 2009
Primary CompletionMay 17, 2017
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 17.2 years ago

Interventions

Carfilzomibdrug

Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.